Apples or Kiwis? Is 23Gy kidney absorbed-dose limit the way to go for radiopharmaceutical therapies?

Clinical trials for radiopharmaceutical therapies (RPTs) are usually limited to 23 Gray absorbed dose to kidneys. However, this value seems arbitrary when considering its source: a publication for external radiation beam therapy (EBRT) dating back to 1991, itself referring to a paper in 1968. The existing limit in fact neglects inherent differences between RPT and EBRT.
In this episode, Nuclear Jimmy and his invited guests Dr. Persi, Dr. Fence,and Mr. RPT discuss the validity of absorbed dose limits for RPTs. They discuss:
#1) Outdated literature
#2) Homogeneous vs. heterogeneous distribution of radiation
#3) Observed differences in kidney toxicities between RPTs
#4) Dose rate differences
#5) Microscopic dose deposition matters!
For our previous encounter, see:
• Myth or Fact? We Canno...

[@miladpeer-firozjaei8971]

😂😂👍

[@LimonaMaria]

😂

[@alifeleparanj3688]

🤣